Castleark Management LLC held its stake in Galapagos NV (NASDAQ:GLPG) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,075 shares of the biotechnology company’s stock at the end of the second quarter. Castleark Management LLC’s holdings in Galapagos NV were worth $465,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of GLPG. Karp Capital Management Corp bought a new position in Galapagos NV in the 1st quarter valued at approximately $206,000. Oxford Asset Management bought a new position in Galapagos NV in the 1st quarter valued at approximately $300,000. Wellington Management Group LLP raised its holdings in Galapagos NV by 9.5% in the 1st quarter. Wellington Management Group LLP now owns 458,088 shares of the biotechnology company’s stock valued at $39,483,000 after buying an additional 39,729 shares during the last quarter. MARSHALL WACE ASIA Ltd bought a new position in Galapagos NV in the 1st quarter valued at approximately $989,000. Finally, Marshall Wace North America L.P. bought a new position in Galapagos NV in the 1st quarter valued at approximately $989,000. Institutional investors and hedge funds own 23.62% of the company’s stock.

Galapagos NV (GLPG) traded down 1.66% during mid-day trading on Tuesday, reaching $100.78. 5,346 shares of the company’s stock were exchanged. Galapagos NV has a one year low of $57.16 and a one year high of $104.12.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://theolympiareport.com/2017/10/17/castleark-management-llc-holds-holdings-in-galapagos-nv-glpg.html.

A number of brokerages recently issued reports on GLPG. Stifel Nicolaus upgraded shares of Galapagos NV from a “hold” rating to a “buy” rating and raised their price objective for the company from $83.00 to $101.00 in a report on Friday, August 11th. Zacks Investment Research upgraded shares of Galapagos NV from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. Cowen and Company reiterated a “buy” rating on shares of Galapagos NV in a report on Thursday, August 10th. BidaskClub lowered shares of Galapagos NV from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $92.00 price objective on shares of Galapagos NV in a report on Thursday, August 10th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $108.14.

Galapagos NV Company Profile

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

Want to see what other hedge funds are holding GLPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Galapagos NV (NASDAQ:GLPG).

Institutional Ownership by Quarter for Galapagos NV (NASDAQ:GLPG)

Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with Analyst Ratings Network's FREE daily email newsletter.